Immatics (IMTX) Stock Forecast & Price Target

IMTX price $7.40 +0.05 +0.68%

Ticker
IMTX
Price
$7.40
Change
+0.05 +0.68%
Market cap ?
$1.11B
P/E ?
-4.10
Dividend yield ?
0.00%
Beta ?
1.36
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
46
Value
55
Quality
32
Growth
50

Stocklytics score rationale: value 55, quality 32, growth 50.

Financials

20182019202020212022202320242025
37700001844900031253000347630001728310005399700015583500048266000

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio…

Forecast

Consensus Buy from 8 analysts. Average price target $16.00, +116.2% versus the current price. Low $15.00. High $17.00.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Analysts have an average 12-month price target of $16.00 for Immatics (IMTX), 116.7% above the current price of $7.38. Of 8 analysts covering the stock, 8 rate it Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.

Forecasts are third-party estimates and often wrong. They are not investment advice.

IMTX price target

12-month price target
Low$15.00
Average$16.00
High$17.00

The average is 116.7% above the current price of $7.38.

Is Immatics a buy or sell?

Of 8 analysts, 8 rate Immatics Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.

Immatics earnings and revenue forecast

Analyst averages on file: 2026, EPS -2.03, revenue $42.55 million. 2027, EPS -2.08, revenue $36.51 million.

IMTX score and fair value

The Stocklytics Score for IMTX is 46 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.

IMTX forecast FAQs

What is the IMTX price target?

$16.00 average, with a published range of $15.00 to $17.00.

Is Immatics a buy or sell?

The consensus is Buy from 8 analysts. This is not a recommendation.

What is the Immatics stock forecast for 2026?

Analysts' average EPS estimate for 2026 on file is -2.03. The average revenue estimate is $42.55 million.

What will IMTX be worth in 2030?

No reliable forecast exists that far out.

When is Immatics's next earnings report?

The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.

Related: Immatics · Financials · Dividends · Compare · AI stocks

Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.

Immatics (IMTX) Stock Forecast & Price Target

IMTX$7.40+0.05 +0.68%

$1.11B

Market Cap

-4.10

P/E

—

Forward P/E

46

Score

Price History